Double-crane Pharmaceutical plans to invest over 90 million yuan to establish new lines to manufacture plastic bottles for medical transfusion. Parent Double-crane will loan 81.91 and 28.68 million yuan to its wholly-owned subsidiaries in Anhui and Wuhan, respectively. The Anhui base will set up two new and upgrade one transfusion plastic bottle line, while Wuhan will build one new line. When fully operational, the company's transfusion production lines will reach more than 40, with total manufacturing capacity of 1.3 billion bottles/packages. The production will shift toward more plastic packaging, which gives better profit margins. Double-crane Pharmaceutical aims to build up its transfusion business into the top local brand. (Click here for more - Chinese Language)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.
Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.
Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.
